<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957671</url>
  </required_header>
  <id_info>
    <org_study_id>03-034</org_study_id>
    <nct_id>NCT00957671</nct_id>
  </id_info>
  <brief_title>Anterior Pituitary Hormone Replacement in Traumatic Brain Injury</brief_title>
  <official_title>Anterior Pituitary Hormone Replacement in Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Moody Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fifteen to twenty percent of adults who suffer a traumatic brain injury (TBI) that requires
      hospitalization and rehabilitation have been found to have growth hormone (GH) deficiency by
      GH stimulation testing. Moreover, abnormalities have also been established for the cortisol
      and thyroid axis. The hypothesis of this proposal is that hormone replacement in TBI patients
      with documented abnormalities in the GH, thyroid, or cortisol axis will improve muscle
      function, body composition, aerobic capacity (GH) and tests of neuropsychologic function (GH,
      thyroid, cortisol).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is designed to screen and detect evidence of pituitary hormone deficiency in
      adults following traumatic brain injury. Growth hormone deficiency will be replaced for a
      period of one year. Subject will not be screened until at least one year following brain
      injury to allow for natural recovery of hormone function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Oxygen Uptake at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Maximum Oxygen Uptake was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Oxygen Uptake After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Maximum Oxygen Uptake was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minute Ventilation at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Minute ventilation was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minute Ventilation After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Minute ventilation was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory Exchange Ratio at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Respiratory exchange ratio was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory Exchange Ratio After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Respiratory exchange ratio was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen Pulse at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Oxygen Pulse was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart. Oxygen pulse is calculated by dividing VO2 consumed (mL/min) by heart rate (beats/min) yielding mL/beat. This provides an estimate of cardiac stroke volume.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen Pulse After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Oxygen Pulse was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart. Oxygen pulse is calculated by dividing VO2 consumed (mL/min) by heart rate (beats/min) yielding mL/beat. This provides an estimate of cardiac stroke volume.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Total recall is a sum of all word list items correctly recalled immediately on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall After 1 Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>One year</time_frame>
    <description>The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Total recall is a sum of all word list items correctly recalled immediately on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by California Verbal Learning Test-II With Delayed Recall at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Delayed recall is a sum of all word list items correctly recalled after a 25 minute delay on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by California Verbal Learning Test-II With Delayed Recall After 1 Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>One year</time_frame>
    <description>The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Delayed recall is a sum of all word list items correctly recalled after a 25 minute delay on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Total Recall at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. Total recall is a measure of the subjects memory immediately after viewing the stimulus page. Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Total Recall After 1 Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. Total recall is a measure of the subjects memory immediately after viewing the stimulus page. Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Delayed Recall at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. The delayed recall is a measure of the subjects memory after a 25 minutes delay. The participants are asked to freely recall and again draw the six figures.Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Delayed Recall After 1 Year of Human Growth Hormone Replacement Therapy</measure>
    <time_frame>one year</time_frame>
    <description>The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. The delayed recall is a measure of the subjects memory after a 25 minutes delay. The participants are asked to freely recall and again draw the six figures.Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by Digit Span Total at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Digit Span; Wechsler Memory Scale III (WMS III).
Digits Forward is a test of digit span (range = 3 to 9 digits) consisting of seven items (each with 2 trials). Digits Backward is a test of digit span (range = 3 to 9 digits); however the participant must provide the presented sequence in reverse order. The test consists of seven items (each with 2 trials). Total score is calculated by adding the scores from forward and backward. Data is reported as raw scores. Score ranges are 0 (lowest) to 32 (highest). A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by Digit Span Total After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Digit Span; Wechsler Memory Scale III (WMS III). Digits Forward is a test of digit span (range = 3 to 9 digits) consisting of seven items (each with 2 trials). Digits Backward is a test of digit span (range = 3 to 9 digits); however the participant must provide the presented sequence in reverse order. The test consists of seven items (each with 2 trials). Total score is calculated by adding the scores from forward and backward. Data is reported as raw scores. Score ranges are 0 (lowest) to 32 (highest). A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by Processing Speed Index at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Processing Speed Index is a subcategory of the Wechsler Adult Intelligence Scale III (WAIS-III). Processing speed refers to the speed of cognitive processes and response output.
This index is comprised of performances on two separate tests of visuomotor speed of information processing ability. On one test (Coding) participants refer to a key on top of a page to translate non-verbal symbols to an alpha-numeric digit. The participants then fill in boxes with the correct symbol assigned to a particular number. On the other test (Symbol Search) participants are asked to visually scan and mark items that are identical to one of two targets. If neither target is shown in the array the participant must mark out the work &quot;NO&quot;. Total correct responses for both task within 120 seconds are recorded.
Ranges are 0 (lowest) to 150 (highest) with 100 being the normal average. A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by Processing Speed Index After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Processing Speed Index is a subcategory of the Wechsler Adult Intelligence Scale III (WAIS-III). Processing speed refers to the speed of cognitive processes and response output.
This index is comprised of performances on two separate tests of visuomotor speed of information processing ability. On one test (Coding) participants refer to a key on top of a page to translate non-verbal symbols to an alpha-numeric digit. The participants then fill in boxes with the correct symbol assigned to a particular number. On the other test (Symbol Search) participants are asked to visually scan and mark items that are identical to one of two targets. If neither target is shown in the array the participant must mark out the work &quot;NO&quot;. Total correct responses for both task within 120 seconds are recorded.
Ranges are 0 (lowest) to 150 (highest) with 100 being the normal average. A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by Letter Fluency at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Letter Fluency is a condition measured as part of the subcategory, Verbal Fluency, in the Delis-Kaplan Executive Function System (D-KEFS). Subjects are asked to name as many words as they can starting with a specified letter for 60 seconds. The words can not be names, places, numbers or grammatical variants of previous answers. Repeated answers are not scored as a correct response. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials and a Letter Fluency Score is given. A higher score is considered better. There is no set range as the score depends on how many correct words the subject relays in the given time period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Function as Measured by Letter Fluency After One Year of Human Growth Hormone Replacement Therapy</measure>
    <time_frame>one year</time_frame>
    <description>Letter Fluency is a condition measured as part of the subcategory, Verbal Fluency, in the Delis-Kaplan Executive Function System (D-KEFS). Subjects are asked to name as many words as they can starting with a specified letter for 60 seconds. The words can not be names, places, numbers or grammatical variants of previous answers. Repeated answers are not scored as a correct response. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials and a Letter Fluency Score is given. A higher score is considered better. There is no set range as the score depends on how many correct words the subject relays in the given time period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression as Measured by the Beck Depression Inventory at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Beck Depression Inventory (BDI-II) is used to measure the severity of depression symptoms. The BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are: 0-13: minimal depression; 14-19: mild; depression; 20-28: moderate depression; 29-63: severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression as Measured by Beck Depression Inventory After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Beck Depression Inventory (BDI-II) is used to measure the severity of depression symptoms. The BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are: 0-13: minimal depression; 14-19: mild; depression; 20-28: moderate depression; 29-63: severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue as Measured Using Fatigue Severity Scale at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Fatigue Severity Scale (FSS) is a measure of fatigue and how that fatigue interferes with life. It is a 9-item scale, with a range from 9 to 63, with a higher number indicating greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Measured Using the Fatigue Severity Scale After One Year of Human Growth Hormone Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Fatigue Severity Scale (FSS) is a measure of fatigue and how that fatigue interferes with life. It is a 9-item scale, with a range from 9 to 63, with a higher number indicating greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Function in Male Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Maximum torque production during isometric contraction of the knee extensor muscles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Function in Male Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Maximum torque production during isometric contraction of the knee extensor muscles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Function in Male Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Maximum torque production during maximal isokinetic contractions at 90 degrees per second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Function in Male Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Maximum torque production during maximal isokinetic contractions at 90 degrees per second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Fatigue as Measured by Biodex Pro 4 at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Muscle fatigue is measured using repetitive isokinetic contractions of the knee extensors at 90 degrees per second. Each subject was asked to produce 40 contractions at full force. Data is presented as % of maximum torque at the 40th contraction in the fatigue protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Fatigue as Measured by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Muscle fatigue is measured using repetitive isokinetic contractions of the knee extensors at 90 degrees per second. Each subject was asked to produce 40 contractions at full force. Data is presented as % of maximum torque at the 40th contraction in the fatigue protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Body mass was calculated from whole body scan taken using a GE Lunar iDEXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Free Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Fat free mass is calculated from whole body scan measured using a GE Lunar iDEXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Free Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Fat free mass is calculated from whole body scan measured on a GE Lunar iDEXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Body Fat as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Body Fat in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Function in Female Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Maximum torque production during isometric contraction of the knee extensor muscles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Function in Female Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy</measure>
    <time_frame>one year</time_frame>
    <description>Maximum torque production during isometric contraction of the knee extensor muscles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Function in Female Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Maximum torque production during maximal isokinetic contractions at 90 degrees per second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Function in Female Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy</measure>
    <time_frame>one year</time_frame>
    <description>Maximum torque production during maximal isokinetic contractions at 90 degrees per second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptual Fatigability as Measured by a Fatigue Rating Scale at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Perceptual fatigue was measured before and directly after performing the muscle fatigue exercise protocol (40 continuous maximal force isokinetic knee extensions at 90 degress per second). Subjects were asked to rate their fatigue on a scale of 0-10 with 0 being no fatigue at all and 10 being extreme fatigue. Data is presented as change in fatigue rating induced by exercise testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptual Fatigability as Measured by a Fatigue Rating Scale After One Year of Human Growth Hormone Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Perceptual fatigue was measured before and directly after performing the muscle fatigue exercise protocol (40 continuous maximal force isokinetic knee extensions at 90 degress per second). Subjects were asked to rate their fatigue on a scale of 0-10 with 0 being no fatigue at all and 10 being extreme fatigue. Data is presented as change in fatigue rating induced by exercise testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy</measure>
    <time_frame>one year</time_frame>
    <description>Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Free Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Fat free mass is calculated from whole body scan measured using a GE Lunar iDEXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Free Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy</measure>
    <time_frame>one year</time_frame>
    <description>Fat free mass is calculated from whole body scan measured on a GE Lunar iDEXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Body Fat in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</measure>
    <time_frame>baseline</time_frame>
    <description>Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Body Fat in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</measure>
    <time_frame>one year</time_frame>
    <description>Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Human Growth Hormone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant human growth hormone (rhGH) self administered daily for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human growth hormone</intervention_name>
    <description>200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)</description>
    <arm_group_label>Human Growth Hormone</arm_group_label>
    <other_name>Genotropin</other_name>
    <other_name>Somatropin</other_name>
    <other_name>hGH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 21 and older.

          -  Documented moderate to severe traumatic brain injury at least one year post injury.

        Exclusion Criteria:

          -  The only absolute exclusionary medication will be an anticoagulant (Coumadin) because
             of the risk of bleeding during the possible muscle biopsy procedure and daily
             injections of rhGH in the GH arm of the study.

          -  Any subject with a history of hepatitis or a 3-fold elevation of liver function tests
             (Alk phos, alanine aminotransferase (ALT), aspartate aminotransferase (AST)). We are
             uncertain of the effects of hormone replacement such as rhGH on the liver, so we will
             exclude any subjects with hepatitis. This exclusion applies only to subjects who would
             be enrolled in the GH arm of the study.

          -  Subjects who are deficient in cortisol or thyroid at screening will be excluded until
             hormone abnormalities have been corrected.

          -  Subjects with chronic pain who are being managed with narcotics will be excluded as
             the effects of central nervous system depressants may interfere with study test
             results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall J Urban, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Medical Branch at Galveston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Transitional Learning Center</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical Branch at Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <results_first_submitted>February 1, 2018</results_first_submitted>
  <results_first_submitted_qc>April 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2018</results_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TBI</keyword>
  <keyword>Traumatic Brain injury</keyword>
  <keyword>Growth hormone deficiency</keyword>
  <keyword>Anterior pituitary hormone</keyword>
  <keyword>Recombinant human growth Hormone</keyword>
  <keyword>Genotropin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects with a history of mild to severe traumatic brain injury were recruited from 2010 to 2014. Subjects were screened for abnormal growth hormone secretion by glucagon stimulation test. 19 subjects were screened for this study. 15 of the subjects met final inclusion/exclusion criteria and began the treatment phase.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Human Growth Hormone</title>
          <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15">15 subjects began the treatment phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15">15 subjects completed the treatment phase of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>15 subjects with a history of mild to severe traumatic brain injury and abnormal growth hormone secretion were enrolled in this trial.</population>
      <group_list>
        <group group_id="B1">
          <title>Human Growth Hormone</title>
          <description>Recombinant human growth hormone (rhGH) self administered daily for one year
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at time of injury</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.3" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Oxygen Uptake at Baseline.</title>
        <description>Maximum Oxygen Uptake was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Oxygen Uptake at Baseline.</title>
          <description>Maximum Oxygen Uptake was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
          <units>mL/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Oxygen Uptake After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Maximum Oxygen Uptake was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Oxygen Uptake After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Maximum Oxygen Uptake was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
          <units>mL/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minute Ventilation at Baseline.</title>
        <description>Minute ventilation was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Minute Ventilation at Baseline.</title>
          <description>Minute ventilation was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
          <units>L/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.4" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minute Ventilation After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Minute ventilation was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Minute Ventilation After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Minute ventilation was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
          <units>L/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.4" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Respiratory Exchange Ratio at Baseline.</title>
        <description>Respiratory exchange ratio was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Exchange Ratio at Baseline.</title>
          <description>Respiratory exchange ratio was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
          <units>ratio of CO2/O2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Respiratory Exchange Ratio After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Respiratory exchange ratio was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Exchange Ratio After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Respiratory exchange ratio was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.</description>
          <units>ratio of CO2/O2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxygen Pulse at Baseline.</title>
        <description>Oxygen Pulse was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart. Oxygen pulse is calculated by dividing VO2 consumed (mL/min) by heart rate (beats/min) yielding mL/beat. This provides an estimate of cardiac stroke volume.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Pulse at Baseline.</title>
          <description>Oxygen Pulse was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart. Oxygen pulse is calculated by dividing VO2 consumed (mL/min) by heart rate (beats/min) yielding mL/beat. This provides an estimate of cardiac stroke volume.</description>
          <units>mL/beat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxygen Pulse After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Oxygen Pulse was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart. Oxygen pulse is calculated by dividing VO2 consumed (mL/min) by heart rate (beats/min) yielding mL/beat. This provides an estimate of cardiac stroke volume.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Pulse After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Oxygen Pulse was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart. Oxygen pulse is calculated by dividing VO2 consumed (mL/min) by heart rate (beats/min) yielding mL/beat. This provides an estimate of cardiac stroke volume.</description>
          <units>mL/beat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall at Baseline.</title>
        <description>The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Total recall is a sum of all word list items correctly recalled immediately on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest).</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year
Recombinant human growth hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall at Baseline.</title>
          <description>The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Total recall is a sum of all word list items correctly recalled immediately on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall After 1 Year of Human Growth Hormone Replacement Therapy.</title>
        <description>The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Total recall is a sum of all word list items correctly recalled immediately on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest).</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall After 1 Year of Human Growth Hormone Replacement Therapy.</title>
          <description>The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Total recall is a sum of all word list items correctly recalled immediately on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by California Verbal Learning Test-II With Delayed Recall at Baseline.</title>
        <description>The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Delayed recall is a sum of all word list items correctly recalled after a 25 minute delay on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest).</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by California Verbal Learning Test-II With Delayed Recall at Baseline.</title>
          <description>The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Delayed recall is a sum of all word list items correctly recalled after a 25 minute delay on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by California Verbal Learning Test-II With Delayed Recall After 1 Year of Human Growth Hormone Replacement Therapy.</title>
        <description>The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Delayed recall is a sum of all word list items correctly recalled after a 25 minute delay on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest).</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by California Verbal Learning Test-II With Delayed Recall After 1 Year of Human Growth Hormone Replacement Therapy.</title>
          <description>The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Delayed recall is a sum of all word list items correctly recalled after a 25 minute delay on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Total Recall at Baseline</title>
        <description>The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. Total recall is a measure of the subjects memory immediately after viewing the stimulus page. Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest).</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Total Recall at Baseline</title>
          <description>The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. Total recall is a measure of the subjects memory immediately after viewing the stimulus page. Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Total Recall After 1 Year of Human Growth Hormone Replacement Therapy.</title>
        <description>The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. Total recall is a measure of the subjects memory immediately after viewing the stimulus page. Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest).</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Total Recall After 1 Year of Human Growth Hormone Replacement Therapy.</title>
          <description>The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. Total recall is a measure of the subjects memory immediately after viewing the stimulus page. Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Delayed Recall at Baseline</title>
        <description>The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. The delayed recall is a measure of the subjects memory after a 25 minutes delay. The participants are asked to freely recall and again draw the six figures.Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest).</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Delayed Recall at Baseline</title>
          <description>The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. The delayed recall is a measure of the subjects memory after a 25 minutes delay. The participants are asked to freely recall and again draw the six figures.Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Delayed Recall After 1 Year of Human Growth Hormone Replacement Therapy</title>
        <description>The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. The delayed recall is a measure of the subjects memory after a 25 minutes delay. The participants are asked to freely recall and again draw the six figures.Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest).</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Delayed Recall After 1 Year of Human Growth Hormone Replacement Therapy</title>
          <description>The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. The delayed recall is a measure of the subjects memory after a 25 minutes delay. The participants are asked to freely recall and again draw the six figures.Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by Digit Span Total at Baseline</title>
        <description>Digit Span; Wechsler Memory Scale III (WMS III).
Digits Forward is a test of digit span (range = 3 to 9 digits) consisting of seven items (each with 2 trials). Digits Backward is a test of digit span (range = 3 to 9 digits); however the participant must provide the presented sequence in reverse order. The test consists of seven items (each with 2 trials). Total score is calculated by adding the scores from forward and backward. Data is reported as raw scores. Score ranges are 0 (lowest) to 32 (highest). A higher score indicates a better outcome.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by Digit Span Total at Baseline</title>
          <description>Digit Span; Wechsler Memory Scale III (WMS III).
Digits Forward is a test of digit span (range = 3 to 9 digits) consisting of seven items (each with 2 trials). Digits Backward is a test of digit span (range = 3 to 9 digits); however the participant must provide the presented sequence in reverse order. The test consists of seven items (each with 2 trials). Total score is calculated by adding the scores from forward and backward. Data is reported as raw scores. Score ranges are 0 (lowest) to 32 (highest). A higher score indicates a better outcome.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by Digit Span Total After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Digit Span; Wechsler Memory Scale III (WMS III). Digits Forward is a test of digit span (range = 3 to 9 digits) consisting of seven items (each with 2 trials). Digits Backward is a test of digit span (range = 3 to 9 digits); however the participant must provide the presented sequence in reverse order. The test consists of seven items (each with 2 trials). Total score is calculated by adding the scores from forward and backward. Data is reported as raw scores. Score ranges are 0 (lowest) to 32 (highest). A higher score indicates a better outcome.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by Digit Span Total After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Digit Span; Wechsler Memory Scale III (WMS III). Digits Forward is a test of digit span (range = 3 to 9 digits) consisting of seven items (each with 2 trials). Digits Backward is a test of digit span (range = 3 to 9 digits); however the participant must provide the presented sequence in reverse order. The test consists of seven items (each with 2 trials). Total score is calculated by adding the scores from forward and backward. Data is reported as raw scores. Score ranges are 0 (lowest) to 32 (highest). A higher score indicates a better outcome.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by Processing Speed Index at Baseline</title>
        <description>Processing Speed Index is a subcategory of the Wechsler Adult Intelligence Scale III (WAIS-III). Processing speed refers to the speed of cognitive processes and response output.
This index is comprised of performances on two separate tests of visuomotor speed of information processing ability. On one test (Coding) participants refer to a key on top of a page to translate non-verbal symbols to an alpha-numeric digit. The participants then fill in boxes with the correct symbol assigned to a particular number. On the other test (Symbol Search) participants are asked to visually scan and mark items that are identical to one of two targets. If neither target is shown in the array the participant must mark out the work &quot;NO&quot;. Total correct responses for both task within 120 seconds are recorded.
Ranges are 0 (lowest) to 150 (highest) with 100 being the normal average. A higher score indicates a better outcome.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by Processing Speed Index at Baseline</title>
          <description>Processing Speed Index is a subcategory of the Wechsler Adult Intelligence Scale III (WAIS-III). Processing speed refers to the speed of cognitive processes and response output.
This index is comprised of performances on two separate tests of visuomotor speed of information processing ability. On one test (Coding) participants refer to a key on top of a page to translate non-verbal symbols to an alpha-numeric digit. The participants then fill in boxes with the correct symbol assigned to a particular number. On the other test (Symbol Search) participants are asked to visually scan and mark items that are identical to one of two targets. If neither target is shown in the array the participant must mark out the work &quot;NO&quot;. Total correct responses for both task within 120 seconds are recorded.
Ranges are 0 (lowest) to 150 (highest) with 100 being the normal average. A higher score indicates a better outcome.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.3" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by Processing Speed Index After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Processing Speed Index is a subcategory of the Wechsler Adult Intelligence Scale III (WAIS-III). Processing speed refers to the speed of cognitive processes and response output.
This index is comprised of performances on two separate tests of visuomotor speed of information processing ability. On one test (Coding) participants refer to a key on top of a page to translate non-verbal symbols to an alpha-numeric digit. The participants then fill in boxes with the correct symbol assigned to a particular number. On the other test (Symbol Search) participants are asked to visually scan and mark items that are identical to one of two targets. If neither target is shown in the array the participant must mark out the work &quot;NO&quot;. Total correct responses for both task within 120 seconds are recorded.
Ranges are 0 (lowest) to 150 (highest) with 100 being the normal average. A higher score indicates a better outcome.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by Processing Speed Index After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Processing Speed Index is a subcategory of the Wechsler Adult Intelligence Scale III (WAIS-III). Processing speed refers to the speed of cognitive processes and response output.
This index is comprised of performances on two separate tests of visuomotor speed of information processing ability. On one test (Coding) participants refer to a key on top of a page to translate non-verbal symbols to an alpha-numeric digit. The participants then fill in boxes with the correct symbol assigned to a particular number. On the other test (Symbol Search) participants are asked to visually scan and mark items that are identical to one of two targets. If neither target is shown in the array the participant must mark out the work &quot;NO&quot;. Total correct responses for both task within 120 seconds are recorded.
Ranges are 0 (lowest) to 150 (highest) with 100 being the normal average. A higher score indicates a better outcome.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.6" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by Letter Fluency at Baseline</title>
        <description>Letter Fluency is a condition measured as part of the subcategory, Verbal Fluency, in the Delis-Kaplan Executive Function System (D-KEFS). Subjects are asked to name as many words as they can starting with a specified letter for 60 seconds. The words can not be names, places, numbers or grammatical variants of previous answers. Repeated answers are not scored as a correct response. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials and a Letter Fluency Score is given. A higher score is considered better. There is no set range as the score depends on how many correct words the subject relays in the given time period.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by Letter Fluency at Baseline</title>
          <description>Letter Fluency is a condition measured as part of the subcategory, Verbal Fluency, in the Delis-Kaplan Executive Function System (D-KEFS). Subjects are asked to name as many words as they can starting with a specified letter for 60 seconds. The words can not be names, places, numbers or grammatical variants of previous answers. Repeated answers are not scored as a correct response. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials and a Letter Fluency Score is given. A higher score is considered better. There is no set range as the score depends on how many correct words the subject relays in the given time period.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Function as Measured by Letter Fluency After One Year of Human Growth Hormone Replacement Therapy</title>
        <description>Letter Fluency is a condition measured as part of the subcategory, Verbal Fluency, in the Delis-Kaplan Executive Function System (D-KEFS). Subjects are asked to name as many words as they can starting with a specified letter for 60 seconds. The words can not be names, places, numbers or grammatical variants of previous answers. Repeated answers are not scored as a correct response. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials and a Letter Fluency Score is given. A higher score is considered better. There is no set range as the score depends on how many correct words the subject relays in the given time period.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Function as Measured by Letter Fluency After One Year of Human Growth Hormone Replacement Therapy</title>
          <description>Letter Fluency is a condition measured as part of the subcategory, Verbal Fluency, in the Delis-Kaplan Executive Function System (D-KEFS). Subjects are asked to name as many words as they can starting with a specified letter for 60 seconds. The words can not be names, places, numbers or grammatical variants of previous answers. Repeated answers are not scored as a correct response. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials and a Letter Fluency Score is given. A higher score is considered better. There is no set range as the score depends on how many correct words the subject relays in the given time period.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression as Measured by the Beck Depression Inventory at Baseline.</title>
        <description>Beck Depression Inventory (BDI-II) is used to measure the severity of depression symptoms. The BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are: 013: minimal depression; 1419: mild; depression; 2028: moderate depression; 2963: severe depression.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Depression as Measured by the Beck Depression Inventory at Baseline.</title>
          <description>Beck Depression Inventory (BDI-II) is used to measure the severity of depression symptoms. The BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are: 013: minimal depression; 1419: mild; depression; 2028: moderate depression; 2963: severe depression.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression as Measured by Beck Depression Inventory After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Beck Depression Inventory (BDI-II) is used to measure the severity of depression symptoms. The BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are: 0-13: minimal depression; 14-19: mild; depression; 20-28: moderate depression; 29-63: severe depression.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Depression as Measured by Beck Depression Inventory After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Beck Depression Inventory (BDI-II) is used to measure the severity of depression symptoms. The BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are: 0-13: minimal depression; 14-19: mild; depression; 20-28: moderate depression; 29-63: severe depression.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue as Measured Using Fatigue Severity Scale at Baseline.</title>
        <description>Fatigue Severity Scale (FSS) is a measure of fatigue and how that fatigue interferes with life. It is a 9-item scale, with a range from 9 to 63, with a higher number indicating greater severity.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue as Measured Using Fatigue Severity Scale at Baseline.</title>
          <description>Fatigue Severity Scale (FSS) is a measure of fatigue and how that fatigue interferes with life. It is a 9-item scale, with a range from 9 to 63, with a higher number indicating greater severity.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue Measured Using the Fatigue Severity Scale After One Year of Human Growth Hormone Therapy.</title>
        <description>Fatigue Severity Scale (FSS) is a measure of fatigue and how that fatigue interferes with life. It is a 9-item scale, with a range from 9 to 63, with a higher number indicating greater severity.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue Measured Using the Fatigue Severity Scale After One Year of Human Growth Hormone Therapy.</title>
          <description>Fatigue Severity Scale (FSS) is a measure of fatigue and how that fatigue interferes with life. It is a 9-item scale, with a range from 9 to 63, with a higher number indicating greater severity.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Function in Male Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 at Baseline.</title>
        <description>Maximum torque production during isometric contraction of the knee extensor muscles.</description>
        <time_frame>baseline</time_frame>
        <population>This is the data for the 10 male subjects enrolled in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Function in Male Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 at Baseline.</title>
          <description>Maximum torque production during isometric contraction of the knee extensor muscles.</description>
          <population>This is the data for the 10 male subjects enrolled in this study.</population>
          <units>Newton-Meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.0" spread="32.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Function in Male Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Maximum torque production during isometric contraction of the knee extensor muscles.</description>
        <time_frame>one year</time_frame>
        <population>This is the data for the 10 male subjects in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Function in Male Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Maximum torque production during isometric contraction of the knee extensor muscles.</description>
          <population>This is the data for the 10 male subjects in this study.</population>
          <units>Newton-Meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.6" spread="37.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Function in Male Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 at Baseline.</title>
        <description>Maximum torque production during maximal isokinetic contractions at 90 degrees per second.</description>
        <time_frame>baseline</time_frame>
        <population>This data is for the 10 male subjects enrolled in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Function in Male Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 at Baseline.</title>
          <description>Maximum torque production during maximal isokinetic contractions at 90 degrees per second.</description>
          <population>This data is for the 10 male subjects enrolled in this study.</population>
          <units>Newton-Meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.2" spread="36.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Function in Male Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Maximum torque production during maximal isokinetic contractions at 90 degrees per second.</description>
        <time_frame>one year</time_frame>
        <population>This data is for the 10 male subjects in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Function in Male Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Maximum torque production during maximal isokinetic contractions at 90 degrees per second.</description>
          <population>This data is for the 10 male subjects in this study.</population>
          <units>Newton-Meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.6" spread="45.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Fatigue as Measured by Biodex Pro 4 at Baseline.</title>
        <description>Muscle fatigue is measured using repetitive isokinetic contractions of the knee extensors at 90 degrees per second. Each subject was asked to produce 40 contractions at full force. Data is presented as % of maximum torque at the 40th contraction in the fatigue protocol.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Fatigue as Measured by Biodex Pro 4 at Baseline.</title>
          <description>Muscle fatigue is measured using repetitive isokinetic contractions of the knee extensors at 90 degrees per second. Each subject was asked to produce 40 contractions at full force. Data is presented as % of maximum torque at the 40th contraction in the fatigue protocol.</description>
          <units>Percent of Maximum Torque</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" spread="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Fatigue as Measured by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Muscle fatigue is measured using repetitive isokinetic contractions of the knee extensors at 90 degrees per second. Each subject was asked to produce 40 contractions at full force. Data is presented as % of maximum torque at the 40th contraction in the fatigue protocol.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Fatigue as Measured by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Muscle fatigue is measured using repetitive isokinetic contractions of the knee extensors at 90 degrees per second. Each subject was asked to produce 40 contractions at full force. Data is presented as % of maximum torque at the 40th contraction in the fatigue protocol.</description>
          <units>Percent of Maximum Torque</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</title>
        <description>Body mass was calculated from whole body scan taken using a GE Lunar iDEXA.</description>
        <time_frame>baseline</time_frame>
        <population>This data is for the 10 male subjects in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</title>
          <description>Body mass was calculated from whole body scan taken using a GE Lunar iDEXA.</description>
          <population>This data is for the 10 male subjects in the study.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.04" spread="18.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
        <time_frame>one year</time_frame>
        <population>This is the data for the 10 male subjects in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
          <population>This is the data for the 10 male subjects in the study.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.55" spread="19.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lean Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline</title>
        <description>Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
        <time_frame>baseline</time_frame>
        <population>This data is for the 10 male subjects enrolled in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Lean Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline</title>
          <description>Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
          <population>This data is for the 10 male subjects enrolled in this study.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.68" spread="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lean Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
        <time_frame>one year</time_frame>
        <population>This data is for the 10 male subjects enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Lean Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
          <population>This data is for the 10 male subjects enrolled in the study.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.70" spread="8.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fat Free Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</title>
        <description>Fat free mass is calculated from whole body scan measured using a GE Lunar iDEXA.</description>
        <time_frame>baseline</time_frame>
        <population>This data is for the 10 male subjects enrolled in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Fat Free Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</title>
          <description>Fat free mass is calculated from whole body scan measured using a GE Lunar iDEXA.</description>
          <population>This data is for the 10 male subjects enrolled in this study.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.19" spread="13.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fat Free Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Fat free mass is calculated from whole body scan measured on a GE Lunar iDEXA.</description>
        <time_frame>one year</time_frame>
        <population>This is the data for the 10 male subjects enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Fat Free Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Fat free mass is calculated from whole body scan measured on a GE Lunar iDEXA.</description>
          <population>This is the data for the 10 male subjects enrolled in the study.</population>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.67" spread="14.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Body Fat as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</title>
        <description>Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.</description>
        <time_frame>baseline</time_frame>
        <population>This data is for the 10 male subjects enrolled in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Body Fat as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</title>
          <description>Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.</description>
          <population>This data is for the 10 male subjects enrolled in this study.</population>
          <units>percent of body fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.47" spread="8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Body Fat in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.</description>
        <time_frame>one year</time_frame>
        <population>This data is for the 10 male subjects in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Body Fat in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.</description>
          <population>This data is for the 10 male subjects in the study.</population>
          <units>percent of body fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Function in Female Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 at Baseline.</title>
        <description>Maximum torque production during isometric contraction of the knee extensor muscles.</description>
        <time_frame>baseline</time_frame>
        <population>This data is for the 5 female subjects enrolled in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Function in Female Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 at Baseline.</title>
          <description>Maximum torque production during isometric contraction of the knee extensor muscles.</description>
          <population>This data is for the 5 female subjects enrolled in this study.</population>
          <units>Newton-Meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.5" spread="26.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Function in Female Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy</title>
        <description>Maximum torque production during isometric contraction of the knee extensor muscles.</description>
        <time_frame>one year</time_frame>
        <population>This data is for the 5 female subjects in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Function in Female Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy</title>
          <description>Maximum torque production during isometric contraction of the knee extensor muscles.</description>
          <population>This data is for the 5 female subjects in the study.</population>
          <units>Newton-Meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.7" spread="34.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Function in Female Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 at Baseline</title>
        <description>Maximum torque production during maximal isokinetic contractions at 90 degrees per second.</description>
        <time_frame>baseline</time_frame>
        <population>This data is for the 5 female subjects enrolled in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Function in Female Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 at Baseline</title>
          <description>Maximum torque production during maximal isokinetic contractions at 90 degrees per second.</description>
          <population>This data is for the 5 female subjects enrolled in this study.</population>
          <units>Newton-Meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.9" spread="12.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Function in Female Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy</title>
        <description>Maximum torque production during maximal isokinetic contractions at 90 degrees per second.</description>
        <time_frame>one year</time_frame>
        <population>This data is for the 5 female subjects enrolled in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Function in Female Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy</title>
          <description>Maximum torque production during maximal isokinetic contractions at 90 degrees per second.</description>
          <population>This data is for the 5 female subjects enrolled in this study.</population>
          <units>Newton-Meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" spread="17.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceptual Fatigability as Measured by a Fatigue Rating Scale at Baseline.</title>
        <description>Perceptual fatigue was measured before and directly after performing the muscle fatigue exercise protocol (40 continuous maximal force isokinetic knee extensions at 90 degress per second). Subjects were asked to rate their fatigue on a scale of 0-10 with 0 being no fatigue at all and 10 being extreme fatigue. Data is presented as change in fatigue rating induced by exercise testing.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Perceptual Fatigability as Measured by a Fatigue Rating Scale at Baseline.</title>
          <description>Perceptual fatigue was measured before and directly after performing the muscle fatigue exercise protocol (40 continuous maximal force isokinetic knee extensions at 90 degress per second). Subjects were asked to rate their fatigue on a scale of 0-10 with 0 being no fatigue at all and 10 being extreme fatigue. Data is presented as change in fatigue rating induced by exercise testing.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceptual Fatigability as Measured by a Fatigue Rating Scale After One Year of Human Growth Hormone Therapy.</title>
        <description>Perceptual fatigue was measured before and directly after performing the muscle fatigue exercise protocol (40 continuous maximal force isokinetic knee extensions at 90 degress per second). Subjects were asked to rate their fatigue on a scale of 0-10 with 0 being no fatigue at all and 10 being extreme fatigue. Data is presented as change in fatigue rating induced by exercise testing.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Perceptual Fatigability as Measured by a Fatigue Rating Scale After One Year of Human Growth Hormone Therapy.</title>
          <description>Perceptual fatigue was measured before and directly after performing the muscle fatigue exercise protocol (40 continuous maximal force isokinetic knee extensions at 90 degress per second). Subjects were asked to rate their fatigue on a scale of 0-10 with 0 being no fatigue at all and 10 being extreme fatigue. Data is presented as change in fatigue rating induced by exercise testing.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</title>
        <time_frame>baseline</time_frame>
        <population>This is the data for the 5 females in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</title>
          <population>This is the data for the 5 females in the study.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.64" spread="10.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy</title>
        <description>Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
        <time_frame>one year</time_frame>
        <population>This data represents the 5 females in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy</title>
          <description>Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
          <population>This data represents the 5 females in the study.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.54" spread="10.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lean Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline</title>
        <description>Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA.</description>
        <time_frame>baseline</time_frame>
        <population>This data is for the 5 female subjects in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Lean Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline</title>
          <description>Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA.</description>
          <population>This data is for the 5 female subjects in the study.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.84" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lean Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
        <time_frame>one year</time_frame>
        <population>This data is for the 5 female subjects in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Lean Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA</description>
          <population>This data is for the 5 female subjects in the study.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.92" spread="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fat Free Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</title>
        <description>Fat free mass is calculated from whole body scan measured using a GE Lunar iDEXA.</description>
        <time_frame>baseline</time_frame>
        <population>This data is for the 5 female subjects in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Fat Free Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</title>
          <description>Fat free mass is calculated from whole body scan measured using a GE Lunar iDEXA.</description>
          <population>This data is for the 5 female subjects in the study.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.31" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fat Free Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy</title>
        <description>Fat free mass is calculated from whole body scan measured on a GE Lunar iDEXA.</description>
        <time_frame>one year</time_frame>
        <population>This is the data for the 5 female subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Fat Free Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy</title>
          <description>Fat free mass is calculated from whole body scan measured on a GE Lunar iDEXA.</description>
          <population>This is the data for the 5 female subjects.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.15" spread="8.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Body Fat in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</title>
        <description>Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.</description>
        <time_frame>baseline</time_frame>
        <population>This data is for the 5 female subjects enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Body Fat in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.</title>
          <description>Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.</description>
          <population>This data is for the 5 female subjects enrolled in the study.</population>
          <units>percent of body fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.92" spread="8.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Body Fat in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</title>
        <description>Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.</description>
        <time_frame>one year</time_frame>
        <population>This data is for the 5 female subjects enrolled in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Growth Hormone</title>
            <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Body Fat in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.</title>
          <description>Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.</description>
          <population>This data is for the 5 female subjects enrolled in this study.</population>
          <units>percent of body fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.74" spread="6.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Human Growth Hormone</title>
          <description>recombinant human growth hormone (rhGH) self administered daily for one year.
Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Randall Urban, MD</name_or_title>
      <organization>University of Texas Medical Branch</organization>
      <phone>409-772-1176</phone>
      <email>rurban@utmb.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

